GlassScriptPhysician profile
Jie Li
NPI 1396340915
$2,934.95
in general payments reported to CMS, 2019-2025
21 companies · $1,071 in 2025
The $1,071 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $641 · 2022: $592 · 2023: $425 · 2024: $206 · 2025: $1,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,621 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,621.15 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $729.11 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $389.60 | 2023-2025 | Ingrezza |
| Sun Pharmaceutical Industries INC. | $378.34 | 2022-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $323.68 | 2022-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $253.83 | 2024-2025 | Zoryve |
| Epi Health, LLC | $169.82 | 2022 | |
| Gilead Sciences, INC. | $125.00 | 2025 | Epclusa |
| Incyte Corporation | $104.74 | 2022-2024 | Opzelura |
| Daiichi Sankyo INC. | $80.00 | 2025 | Enhertu |
| Madrigal Pharmaceuticals | $69.09 | 2025 | Rezdiffra |
| Janssen Biotech, INC. | $56.40 | 2022 | |
| Lnhc, INC | $48.81 | 2025 | Zelsuvmi |
| Ucb, INC. | $38.90 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $31.13 | 2024 | Sotyktu |
| Genzyme Corporation | $25.28 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $23.64 | 2021 | |
| Intercept Pharmaceuticals, INC. | $19.61 | 2024 | |
| Amarin Pharma, INC. | $19.46 | 2021 | |
| Ibsa Pharma INC. | $19.12 | 2021 | |
| Almirall LLC | $15.00 | 2022 | |
| Pfizer INC. | $14.39 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jie Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.